发明名称 NOVEL PYRROLE DERIVATIVES
摘要 There are provided inter alia compounds of formula (I) wherein R1, R2, R3, R4a and R4b are as defined in the specification and their use in therapy, especially in the treatment of bacterial (e.g. pneumococcal) infections.;
申请公布号 US2014309193(A1) 申请公布日期 2014.10.16
申请号 US201214360365 申请日期 2012.12.05
申请人 University of Leicester 发明人 Andrew Peter William;Lonnen Rana;Damaso Mafalda Pires;Frickel Fritz-Frieder;Hirst Simon Christopher;Davies Mark William;Hamza Daniel
分类号 C07D207/36;C07D207/38;C07C237/20;C07F9/572;C07D401/12;C07C229/42;C07D401/14 主分类号 C07D207/36
代理机构 代理人
主权项 1. A compound of formula (I): wherein: R1 and R2 are independently selected from —C(O)NR5R6, —C(O)OR7, CN, —C(O)R7, —C(O)NHC(O)R7, —NO2, —SO3R7, —SO2R7, —SOR7, —SO2NR5R6, —SO2NH—C(O)OR8, —POR21R22 and optionally substituted phenyl or heteroaryl; R3 is optionally substituted phenyl; R4a and R4b are independently selected from hydrogen; C1-C6 alkyl which alkyl group may optionally be substituted by hydroxyl, COOR12 or CONR13R14; aryl and —C1-C3 alkylaryl in which said aryl groups may be optionally substituted; R5 and R6 are independently selected from: (a) hydrogen,(b) C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C10 cycloalkyl, C5-C10 cycloalkenyl, heterocyclyl, —C1-C3 alkyl-C3-C10 cycloalkyl, —C1-C3 alkyl-C5-C10 cycloalkenyl or —C1-C3 alkylheterocyclyl, or R5 and R6 together with the N to which they are attached may form a 5- or 6-membered heterocyclic ring optionally containing a further heteroatom selected from O, S and NR9, in which any of the aforementioned R5 and R6 groups may be optionally substituted by a group selected from cyano, C1-C6 alkoxy, C1-C6 fluoroalkoxy, C1-C6 alkyl, C1-C6 fluoroalkyl and —C(O)NRaRb, where Ra and Rb are independently selected from hydrogen and C1-C6 alkyl, and any of the aforementioned R5 and R6 groups may be optionally substituted by one or more halogen atoms, and(c) aryl, heteroaryl, C1-C3 alkylaryl and —C1-C3 alkylheteroaryl, said aryl and heteroaryl groups being optionally substituted; R7 is selected from: (a) C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C10 cycloalkyl, C5-C10 cycloalkenyl, heterocyclyl, —C1-C3 alkyl-C3-C10 cycloalkyl, —C1-C3 alkyl-C5-C10 cycloalkenyl or —C1-C3 alkylheterocyclyl, in which any of the aforementioned R7 groups may be optionally substituted by a group selected from cyano, C1-C6 alkoxy, C1-C6 fluoroalkoxy, C1-C6 alkyl, C1-C6 fluoroalkyl and —C(O)NRaRb, where Ra and Rb are independently selected from hydrogen and C1-C6 alkyl, and any of the aforementioned R7 groups may be optionally substituted by one or more halogen atoms, and(b) aryl, heteroaryl, C1-C3 alkylaryl and —C1-C3 alkylheteroaryl, said aryl and heteroaryl groups being optionally substituted; R8 is C1-C6 alkyl; R9 is hydrogen, C1-C6 alkyl; —C(O)R10 or —C(O)OR11; R10 is C1-C6 alkyl; R11 is C1-C6 alkyl; R12 is C1-C6 alkyl; R13 is hydrogen or C1-C6 alkyl; R14 is hydrogen or C1-C6 alkyl; and R21 and R22 are independently selected from C1-C6 alkyl and C1-C6 hydroxyalkyl; or a pharmaceutically acceptable prodrug derivative thereof, or a pharmaceutically acceptable salt or solvate thereof; provided that the compound is not: a) diethyl 3,4-dihydroxy-1-(4-methoxyphenyl)-1H-pyrrole-2,5-dicarboxylate; b) diethyl 3,4-dihydroxy-1-phenyl-1H-pyrrole-2,5-dicarboxylate; c) dimethyl 3,4-dihydroxy-1-(4-bromophenyl)-1H-pyrrole-2,5-dicarboxylate; d) dimethyl 3,4-dihydroxy-1-(4-chlorophenyl)-1H-pyrrole-2,5-dicarboxylate; e) di-tert-butyl 3,4-dihydroxy-1-(4-nitrophenyl)-1H-pyrrole-2,5-dicarboxylate; f) dimethyl 3,4-dihydroxy-1-(4-methoxyphenyl)-1H-pyrrole-2,5-dicarboxylate; g) dimethyl 3,4-dihydroxy-1-phenyl-1H-pyrrole-2,5-dicarboxylate; h) diethyl 3,4-bis(acetyloxy)-1-phenyl-1H-pyrrole-2,5-dicarboxylate; or i) dimethyl 3,4-bis(acetyloxy)-1-phenyl-1H-pyrrole-2,5-dicarboxylate.
地址 Leicester GB